{"id":15446,"date":"2025-03-20T18:13:43","date_gmt":"2025-03-20T17:13:43","guid":{"rendered":"https:\/\/www.clarkemodet.com\/?p=15446"},"modified":"2025-03-20T18:15:48","modified_gmt":"2025-03-20T17:15:48","slug":"anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects","status":"publish","type":"post","link":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/","title":{"rendered":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On March 20, the Brazilian Health Regulatory Agency (Anvisa) published an update to the List of Reference Medicines (LMR), a key regulatory milestone for the pharmaceutical industry in Brazil. The LMR establishes which innovative drugs serve as the basis for generics and similar medications, ensuring standards of safety, efficacy, and quality.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This update does not affect already registered medicines but may have a direct impact on ongoing projects and new regulatory submissions. The main areas affected include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ongoing Development Projects<\/strong> \u2013 Companies must review whether the reference medicines they are using remain on the LMR or have been replaced. These changes can influence technical requirements and regulatory timelines.<\/li>\n\n\n\n<li><strong>Generic and Similar Drug Registration<\/strong> \u2013 If a reference medicine has been modified, manufacturers must ensure their products comply with Anvisa&#8217;s updated regulations.<\/li>\n\n\n\n<li><strong>Continuous Monitoring<\/strong> \u2013 The update may create opportunities for new product launches or require strategic adjustments in existing projects.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key Actions for Companies<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Given these changes, it is crucial for companies to <strong>carefully analyze the new LMR<\/strong> to prevent regulatory and operational impacts on ongoing projects. Recommended actions include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Verify whether the reference medicine used in your projects is still on the list.<\/li>\n\n\n\n<li>If a substitution occurred, assess its impact on regulatory and technical processes.<\/li>\n\n\n\n<li>Consult with specialists to align with Anvisa\u2019s updated guidelines.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">If you need further insights into how this update may affect your projects and want to ensure compliance with regulatory requirements, <strong>our team is available to assist you<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On March 20, the Brazilian Health Regulatory Agency (Anvisa) published an update to the List of Reference Medicines (LMR), a key regulatory milestone for the pharmaceutical industry in Brazil. The LMR establishes which innovative drugs serve as the basis for generics and similar medications, ensuring standards of safety, efficacy, and quality. This update does not [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":15437,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[79],"tags":[],"country":[30],"industry":[98,97],"class_list":["post-15446","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legislative-news","country-br","industry-chemical-industry","industry-pharma-and-biotechnology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects - ClarkeModet<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects\" \/>\n<meta property=\"og:description\" content=\"On March 20, the Brazilian Health Regulatory Agency (Anvisa) published an update to the List of Reference Medicines (LMR), a key regulatory milestone for the pharmaceutical industry in Brazil. The LMR establishes which innovative drugs serve as the basis for generics and similar medications, ensuring standards of safety, efficacy, and quality. This update does not [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\" \/>\n<meta property=\"og:site_name\" content=\"ClarkeModet\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T17:13:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-20T17:15:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_social.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Violeta Jim\u00e9nez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_social.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@clarkemodet\" \/>\n<meta name=\"twitter:site\" content=\"@clarkemodet\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Violeta Jim\u00e9nez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\"},\"author\":{\"name\":\"Violeta Jim\u00e9nez\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/a0b997c100260c6c2ded81367bf0ff76\"},\"headline\":\"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects\",\"datePublished\":\"2025-03-20T17:13:43+00:00\",\"dateModified\":\"2025-03-20T17:15:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg\",\"articleSection\":[\"Legislative news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\",\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\",\"name\":\"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects - ClarkeModet\",\"isPartOf\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg\",\"datePublished\":\"2025-03-20T17:13:43+00:00\",\"dateModified\":\"2025-03-20T17:15:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage\",\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg\",\"contentUrl\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg\",\"width\":1280,\"height\":960},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#website\",\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/\",\"name\":\"ClarkeModet\",\"description\":\"Somos el mayor grupo especializado en la protecci\u00f3n de tu Propiedad Industrial e Intelectual en pa\u00edses de habla hispana y portuguesa.\",\"publisher\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oldweb2025.clarkemodet.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#organization\",\"name\":\"ClarkeModet\",\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2023\/03\/AF_CLARKEMODET_VP_POS_RGB.png\",\"contentUrl\":\"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2023\/03\/AF_CLARKEMODET_VP_POS_RGB.png\",\"width\":1431,\"height\":812,\"caption\":\"ClarkeModet\"},\"image\":{\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/clarkemodet\",\"https:\/\/www.linkedin.com\/company\/clarkemodet\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/a0b997c100260c6c2ded81367bf0ff76\",\"name\":\"Violeta Jim\u00e9nez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/53acb3c168d98de48c16699404aa91b4ff6c6938a0a8b80a6e35ada20c908c82?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/53acb3c168d98de48c16699404aa91b4ff6c6938a0a8b80a6e35ada20c908c82?s=96&d=mm&r=g\",\"caption\":\"Violeta Jim\u00e9nez\"},\"url\":\"https:\/\/oldweb2025.clarkemodet.com\/en\/author\/vjimenezb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects - ClarkeModet","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects","og_description":"On March 20, the Brazilian Health Regulatory Agency (Anvisa) published an update to the List of Reference Medicines (LMR), a key regulatory milestone for the pharmaceutical industry in Brazil. The LMR establishes which innovative drugs serve as the basis for generics and similar medications, ensuring standards of safety, efficacy, and quality. This update does not [&hellip;]","og_url":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/","og_site_name":"ClarkeModet","article_published_time":"2025-03-20T17:13:43+00:00","article_modified_time":"2025-03-20T17:15:48+00:00","og_image":[{"width":900,"height":600,"url":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_social.jpg","type":"image\/jpeg"}],"author":"Violeta Jim\u00e9nez","twitter_card":"summary_large_image","twitter_title":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects","twitter_image":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_social.jpg","twitter_creator":"@clarkemodet","twitter_site":"@clarkemodet","twitter_misc":{"Written by":"Violeta Jim\u00e9nez","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#article","isPartOf":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/"},"author":{"name":"Violeta Jim\u00e9nez","@id":"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/a0b997c100260c6c2ded81367bf0ff76"},"headline":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects","datePublished":"2025-03-20T17:13:43+00:00","dateModified":"2025-03-20T17:15:48+00:00","mainEntityOfPage":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/#organization"},"image":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage"},"thumbnailUrl":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg","articleSection":["Legislative news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/","url":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/","name":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects - ClarkeModet","isPartOf":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage"},"image":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage"},"thumbnailUrl":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg","datePublished":"2025-03-20T17:13:43+00:00","dateModified":"2025-03-20T17:15:48+00:00","breadcrumb":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#primaryimage","url":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg","contentUrl":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2025\/03\/anvisa_destacada.jpg","width":1280,"height":960},{"@type":"BreadcrumbList","@id":"https:\/\/oldweb2025.clarkemodet.com\/en\/legislative-news\/anvisa-updates-the-list-of-reference-medicines-impact-on-pharmaceutical-projects\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oldweb2025.clarkemodet.com\/en\/"},{"@type":"ListItem","position":2,"name":"Anvisa Updates the List of Reference Medicines: Impact on Pharmaceutical Projects"}]},{"@type":"WebSite","@id":"https:\/\/oldweb2025.clarkemodet.com\/#website","url":"https:\/\/oldweb2025.clarkemodet.com\/","name":"ClarkeModet","description":"Somos el mayor grupo especializado en la protecci\u00f3n de tu Propiedad Industrial e Intelectual en pa\u00edses de habla hispana y portuguesa.","publisher":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oldweb2025.clarkemodet.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/oldweb2025.clarkemodet.com\/#organization","name":"ClarkeModet","url":"https:\/\/oldweb2025.clarkemodet.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/logo\/image\/","url":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2023\/03\/AF_CLARKEMODET_VP_POS_RGB.png","contentUrl":"https:\/\/oldweb2025.clarkemodet.com\/wp-content\/uploads\/2023\/03\/AF_CLARKEMODET_VP_POS_RGB.png","width":1431,"height":812,"caption":"ClarkeModet"},"image":{"@id":"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/clarkemodet","https:\/\/www.linkedin.com\/company\/clarkemodet\/"]},{"@type":"Person","@id":"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/a0b997c100260c6c2ded81367bf0ff76","name":"Violeta Jim\u00e9nez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oldweb2025.clarkemodet.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/53acb3c168d98de48c16699404aa91b4ff6c6938a0a8b80a6e35ada20c908c82?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/53acb3c168d98de48c16699404aa91b4ff6c6938a0a8b80a6e35ada20c908c82?s=96&d=mm&r=g","caption":"Violeta Jim\u00e9nez"},"url":"https:\/\/oldweb2025.clarkemodet.com\/en\/author\/vjimenezb\/"}]}},"_links":{"self":[{"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/posts\/15446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/comments?post=15446"}],"version-history":[{"count":2,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/posts\/15446\/revisions"}],"predecessor-version":[{"id":15448,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/posts\/15446\/revisions\/15448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/media\/15437"}],"wp:attachment":[{"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/media?parent=15446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/categories?post=15446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/tags?post=15446"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/country?post=15446"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/oldweb2025.clarkemodet.com\/en\/wp-json\/wp\/v2\/industry?post=15446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}